Navigation Links
Standard Heart Drugs Won't Ease Pulmonary Hypertension
Date:5/18/2011

WEDNESDAY, May 18 (HealthDay News) -- Although commonly used to treat heart disease, aspirin and simvastatin offer no benefit to patients suffering from pulmonary arterial hypertension, or PAH, a progressive disease characterized by increased blood pressure in the arteries of the lungs, according to new research.

In a study funded by the U.S. National Institutes of Health, researchers divided 65 patients into four groups: one receiving aspirin; one taking simvastatin; one receiving both drugs; and one in which patients received a placebo (or dummy pill).

"Surprisingly, we found no evidence that aspirin or simvastatin had beneficial clinical effects in this population," said Dr. Steven Kawut, study lead author and associate professor of medicine and epidemiology at the University of Pennsylvania School of Medicine.

After taking the assigned medication for six months, patients were asked to see how far they could walk in six minutes. The distance tended to be shorter in the simvastatin group, and no difference was seen between the aspirin and placebo patients.

Following these early results, the U.S. National Heart, Lung, and Blood Institute discontinued the study based on a recommendation from the Data and Safety Monitoring Board.

"The results of this study do not support the routine treatment of PAH with these medications," Kawut said in an American Thoracic Society news release.

The findings are scheduled to be presented Wednesday at the American Thoracic Society international conference in Denver.

PAH, which is incurable, causes shortness of breath, dizziness and fatigue, and can lead to heart failure and death.

The researchers concluded that both aspirin and simvastatin may be prescribed for usual clinical indications in patients with PAH, but should not be administered specifically to treat PAH.

"The findings show the importance of subjecting traditional cardiovascular therapies and drugs which appear effective in the laboratory to placebo-controlled [randomized clinical trials] in humans before recommending their use," Kawut said.

Research presented at meetings is considered preliminary until published in a peer-reviewed journal.

More information

The U.S. National Heart, Lung, and Blood Institute provides more information on treatments for pulmonary arterial hypertension.

-- Mary Elizabeth Dallas

SOURCE: American Thoracic Society, news release, May 18, 2011


'/>"/>
Copyright©2010 ScoutNews,LLC.
All rights reserved  

Related medicine news :

1. eHealthObjects chooses Elsevier/Gold Standard drug database
2. Human Factors/Ergonomics research leads to improved bunk bed safety standards
3. IOM recommends standards to achieve reliable clinical practice guidelines
4. Quality standards for widely used medicines strengthened
5. Federal Supply Schedule pricing added to ProspectoRx from Elsevier/Gold Standard
6. Standard Exams Might Not Catch Full Potential of Brain Damaged Patients
7. Community oncology: Ensuring the best standards of care
8. FDA Panel Recommends Tougher Standards for External Defibrillators
9. FDA Looking at Tougher Standards for External Defibrillators
10. FDA Looking for Tougher Standards for External Defibrillators
11. Universal standards proposed for prescription container labels to help reduce medication misuse
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Standard Heart Drugs Won't Ease Pulmonary Hypertension
(Date:4/28/2017)... york (PRWEB) , ... April 28, 2017 , ... ... to announce that Aditya Patel M.D. has joined the revolutionary endoscopic practice under ... and board certification in Interventional Pain Medicine. The patented, revolutionary eDiscSculpt Technique created ...
(Date:4/28/2017)... ... April 28, 2017 , ... From April 30 to ... Care Medicine will host industry leaders for the annual spring Convention & Expo, ... the industry adapt to the issues currently affecting urgent care and on-demand healthcare. ...
(Date:4/28/2017)... ... 2017 , ... Bill Howe started his sewer and drain company in 1980 ... joined the team, the Bill Howe brand was born and they began cultivating their ... back to the San Diego community in which they worked, lived and were raising ...
(Date:4/28/2017)... ... April 28, 2017 , ... Phytomer USA ... region. Côté has 20+ years of experience within the beauty industry, ranging from ... an array of high-end cosmetic brands, retail brands and outlets in Canada and ...
(Date:4/28/2017)... CA (PRWEB) , ... April 28, 2017 , ... NuevaCare, ... cities as diverse as Millbrae, Burlingame, and Palo Alto, is proud to announce information ... interested persons to bookmark and read organized content on topics such as home care ...
Breaking Medicine News(10 mins):
(Date:4/20/2017)...  Zimmer Biomet Holdings, Inc. (NYSE and SIX: ZBH), ... it will be participating in the Deutsche Bank Securities ... in Boston, Massachusetts on Wednesday, ... a.m. Eastern Time. A live webcast of ... Relations website at http://investor.zimmerbiomet.com .  The webcast will ...
(Date:4/20/2017)... --  ZappRx, Inc ., a digital health company focused on ... it closed $25 million in Series B funding led by ... Seattle that is part of a ... B round included participation from SR One , who ... (formerly Google Ventures). As part of the financing, ...
(Date:4/20/2017)... DUBLIN , April 20, 2017 ... "Latin America Pharmaceutical Contract Manufacturing Services Market Analysis By Service ... And Segment Forecasts, 2014 - 2025" report to their ... The Latin ... USD 21.0 billion by 2025 Low drug registration ...
Breaking Medicine Technology: